Cardiff Oncology, Inc. (CRDF) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Cardiff Oncology, Inc.'s filing signal turned negative.

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies by targeting tumor vulnerabilities with its lead drug candidate, onvansertib, a highly selective oral PLK1 inhibitor. The company is investigating onvansertib in combination with standard-of-care treatments for indications including RAS-mutated metastatic colorectal cancer (mCRC), and is supporting investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple-negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Clinical development incorporates tumor genomics and biomarker assays to refine patient selection and response assessment. Cardiff Oncology operates in a single business segment, with all principal operations and decision-making functions located in the U.S.

The company generates minimal revenue from sales-based or usage-based royalties on legacy intellectual property licenses, unrelated to its lead drug candidate, onvansertib.